A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
Completed · Phase 3 · NCT03417102
Conditions: Hemophilia A, Hemophilia B
At a glance
- Research payments reported, 2025
- $2,250
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 60
About the trial
- Sponsor
- Genzyme, a Sanofi Company
- Tested
- fitusiran (drug), Bypassing agents (drug)
- Dates
- Started 2018-02-14; completion 2021-06-23
- Results posted
- Yes
The purpose of this study was to determine the frequency of bleeding episodes in participants receiving fitusiran as prophylactic treatment of hemophilia compared to participants who were assigned to continue with their regular medication. In addition, the study assessed safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).
From ClinicalTrials.gov, last updated 2022-03-28. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Genzyme Corporation reported $2,250 in research payments for this study in 2025 (6 payments).
Products named: Qfitlia
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $2,250
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.